High-value oncology deals drive China's drug licensing boom [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
Once considered a nation with expertise in generic and “me-too” drug manufacturing, China is moving away from this reputation by leaning into the strategic development of first-class or best-in-class innovative therapies across pharma and biotech. These efforts are supported by the rapid expansion of China's clinical trial ecosystem, which saw the country take the lead in global study initiations in 2024, as shown by analysis by GlobalData, the parent company of Pharmaceutical Technology China's regulatory system is also poised for continued growth, with swift investigational new drug application (IND) processing playing a key role in timeline acceleration. As R&D efforts accelerate across therapy areas, including oncology, immunology and cardiometabolic health, Western companies are increasingly seeking out deals with Chinese biotech and pharma. This comes as they look to bulk out their pipelines with high-quality, cost-effective therapies in anticipation of the looming patent
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancerBusiness Wire
- Matan Companies Signs 161,500 SF Lease with MCPS at 750 Progress Way in Gaithersburg, MD [Yahoo! Finance]Yahoo! Finance
- uMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical TrialsPR Web
- How New Deals and Diverging Analyst Views Are Rewriting the Story for AstraZeneca [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 12/16/25 - Form 6-K
- 12/16/25 - Form 6-K
- 12/4/25 - Form 6-K
- AZN's page on the SEC website